GLPwatch
Ozempic vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) and Xultophy (liraglutide) are both injectable medications made by Novo Nordisk for type 2 diabetes. Ozempic is also approved to reduce cardiovascular risk and treat chronic kidney disease, while Xultophy is not. Both are given as shots under the skin, but Ozempic is a single active ingredient, whereas Xultophy combines two active ingredients (liraglutide and insulin degludec).
AI summary of the sources below.
| Ozempic | Xultophy | |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Manufacturer | novo-nordisk | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes, cardiovascular risk reduction, chronic kidney disease | type 2 diabetes |
| Label updated | 2026-01-30 | 2025-10-14 |